[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201509835RA - (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same - Google Patents

(+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same

Info

Publication number
SG11201509835RA
SG11201509835RA SG11201509835RA SG11201509835RA SG11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA
Authority
SG
Singapore
Prior art keywords
methyl
oxopyridin
imidazolidine
difluorophenyl
dione
Prior art date
Application number
SG11201509835RA
Other languages
English (en)
Inventor
Noriyuki Kamei
Daigo KAMIMURA
Yoshitake SUMIKAWA
Shota TOKUOKA
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Publication of SG11201509835RA publication Critical patent/SG11201509835RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quick-Acting Or Multi-Walled Pipe Joints (AREA)
SG11201509835RA 2013-06-07 2014-06-06 (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same SG11201509835RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013120692 2013-06-07
PCT/JP2014/065060 WO2014196623A1 (fr) 2013-06-07 2014-06-06 (+)-5-(3,4-difluorophényl)-5-[(3-méthyl-2-oxopyridin-1(2h)-yl)méthyl]- imidazolidine-2,4-dione et médicament la contenant

Publications (1)

Publication Number Publication Date
SG11201509835RA true SG11201509835RA (en) 2015-12-30

Family

ID=52008252

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509835RA SG11201509835RA (en) 2013-06-07 2014-06-06 (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same

Country Status (19)

Country Link
US (1) US9518041B2 (fr)
EP (1) EP3006437B1 (fr)
JP (1) JP6247689B2 (fr)
KR (2) KR102321814B1 (fr)
CN (1) CN105531270B (fr)
AU (1) AU2014275835B2 (fr)
BR (1) BR112015030490B1 (fr)
CA (1) CA2913858C (fr)
ES (1) ES2818931T3 (fr)
HK (1) HK1221219A1 (fr)
IL (1) IL242861B (fr)
MX (1) MX364780B (fr)
MY (1) MY173075A (fr)
NZ (1) NZ714700A (fr)
PH (1) PH12015502661B1 (fr)
RU (1) RU2668072C2 (fr)
SG (1) SG11201509835RA (fr)
TW (1) TWI636782B (fr)
WO (1) WO2014196623A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014196624A1 (fr) * 2013-06-07 2014-12-11 科研製薬株式会社 Composition pour maintenir la fonction plaquettaire
CN107304205B (zh) * 2016-04-22 2020-10-30 上海医药工业研究院 一种马拉韦罗中间体及其制备方法
AU2017332937B2 (en) * 2016-09-23 2021-01-14 Kaken Pharmaceutical Co., Ltd. Method for producing (R)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and intermediate for producing same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1370536A1 (fr) * 2001-03-15 2003-12-17 AstraZeneca AB Inhibiteurs de metalloproteinase
EP1431285B1 (fr) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Derives d'acide hydroxamique inverse
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
EP1546109A4 (fr) 2002-10-04 2005-11-09 Bristol Myers Squibb Co Derives d'hydantoine en tant qu'inhibiteurs de metalloproteinases matricielles et/ou de l'enzyme de conversion de tnf-alpha (tace)
US7132432B2 (en) 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
GB0405101D0 (en) 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
MX2007000668A (es) 2004-07-16 2007-03-08 Schering Corp Derivados de hidantoina para el tratamiento de trastornos inflamatorios.
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US20110082133A1 (en) * 2008-06-17 2011-04-07 Takashi Kamikubo Pyridone compounds
AR073741A1 (es) 2008-09-24 2010-12-01 Schering Corp Derivados heterociclicos de hidantoina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias, tales como psoriasis o artritis
US8569336B2 (en) * 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
US9447072B2 (en) * 2011-12-09 2016-09-20 Kaken Pharmaceutical Co., Ltd. Pyridone derivative and pharmaceutical containing same

Also Published As

Publication number Publication date
JPWO2014196623A1 (ja) 2017-02-23
MX2015016828A (es) 2016-04-11
HK1221219A1 (zh) 2017-05-26
WO2014196623A1 (fr) 2014-12-11
BR112015030490B1 (pt) 2022-01-18
BR112015030490A2 (pt) 2017-07-25
CA2913858C (fr) 2021-07-20
MY173075A (en) 2019-12-24
MX364780B (es) 2019-05-07
CN105531270B (zh) 2017-09-05
KR102379801B1 (ko) 2022-03-28
CA2913858A1 (fr) 2014-12-11
PH12015502661A1 (en) 2016-03-07
IL242861B (en) 2018-08-30
RU2668072C2 (ru) 2018-09-27
CN105531270A (zh) 2016-04-27
US20160130248A1 (en) 2016-05-12
AU2014275835B2 (en) 2018-08-16
NZ714700A (en) 2020-09-25
EP3006437B1 (fr) 2020-08-05
TW201536285A (zh) 2015-10-01
KR20210133326A (ko) 2021-11-05
PH12015502661B1 (en) 2016-03-07
TWI636782B (zh) 2018-10-01
EP3006437A4 (fr) 2017-03-15
RU2015156531A (ru) 2017-07-14
EP3006437A1 (fr) 2016-04-13
ES2818931T3 (es) 2021-04-14
KR102321814B1 (ko) 2021-11-05
US9518041B2 (en) 2016-12-13
KR20160016834A (ko) 2016-02-15
AU2014275835A1 (en) 2015-12-24
JP6247689B2 (ja) 2017-12-13

Similar Documents

Publication Publication Date Title
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HK1223351A1 (zh) 嘧啶衍生物作為激酶抑制劑
ZA201602220B (en) Heterocyclic compounds and uses thereof
EP3076878A4 (fr) Accessoire de planche de surf pour retenir la planche de surf et pour des urgences médicales
SG11201600028YA (en) Substituted aminopyrimidine compounds and methods of use
SG11201510179PA (en) Amino-triazine derivatives and pharmaceutical composition containing said derivatives
ZA201508118B (en) Herbicidally active (alkynyl-phenyl)-substituted cyclic dione compounds and derivatives thereof
EP3020714A4 (fr) Composé imidazole-dicétone et son utilisation
PL2634174T3 (pl) Zawierająca azot pochodna heterocykliczna mająca grupę 2-iminową i zawierający ją środek do zwalczania szkodników
EP3060559A4 (fr) Procédé amélioré pour préparer du ((3s,5r)-5-((1h-1,2,4-triazol-1-yl)méthyl)-5-(2,4-difluorophényl)tétrahydrofuran-3-yl)méthyl-4-méthylbenzènesulfonate
EP3009426A4 (fr) Dérivé de 4-alcynylimidazole et médicament le comprenant en tant que principe actif
IL240875B (en) Heterocyclic compounds and pharmaceutical preparations containing them
HK1221219A1 (zh) -二氟苯基 -甲基- -氧吡啶- -基 甲基 咪唑烷- -二酮及含有該化合物的藥物
EP3006420A4 (fr) Corps fritté céramique et élément anticorrosion, filtre et élément anti-halo formés par son utilisation
IL265481B (en) Method for the production of (r)-5-(4,3-difluorophenyl)-5-[(3-methyl-2-oxopyridine-1(h2)-yl)methyl]imidazolidine-4,2-dione and intermediates for their production
HK1222655A1 (zh) -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑
IL245983B (en) Biologically active insulin derivatives
EP3013333A4 (fr) Composés hétérocycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c
TH1501007248A (th) (+)-5-(3,4ไดฟลูออโรฟีนิล)-5-[(3-เมธิล-2-ออกโซไพริดิน-1(2h)-อิล)เมธิล] อิมิดาโซลิดีน-2,4-ไดโอน และ ยาที่ประกอบด้วยสิ่งเดียวกันนั้น
EP3089974A4 (fr) Nouveaux dérivés d'imidazolidine-2,4-dione
EP3089975A4 (fr) Nouveaux dérivés d'imidazolidine-2,4-dione
GB201610823D0 (en) Heterocyclic compounds and medical uses